Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia.


Journal

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
ISSN: 1550-9397
Titre abrégé: J Clin Sleep Med
Pays: United States
ID NLM: 101231977

Informations de publication

Date de publication:
01 10 2023
Historique:
pmc-release: 01 10 2024
medline: 5 10 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: ppublish

Résumé

To evaluate 6-month efficacy and safety of low-sodium oxybate in people with idiopathic hypersomnia during an open-label extension period (OLE) of a phase 3 clinical trial. Efficacy measures included the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS), Patient Global Impression of Change (PGIc), Functional Outcomes of Sleep Questionnaire, short version (FOSQ-10), and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). Treatment-emergent adverse events were collected throughout the OLE. The OLE population included 106 participants. Most were female (71%) and White (83%), and the mean (SD) age was 41.0 (13.8) years. ESS scores decreased (improved) during the OLE (mean [SD], study baseline: 16.3 [2.8]; OLE week 2: 6.7 [4.7]; OLE end: 5.3 [3.7]), and IHSS total scores trended toward a decrease (study baseline: 32.6 [7.3]; OLE week 2: 16.2 [8.9]; OLE end: 14.8 [8.6]. Median (minimum, maximum) paired differences from OLE week 2 to OLE end were ESS, -1.0 (-20, 7; nominal Efficacy and safety of low-sodium oxybate were maintained or improved during the 6-month OLE, supporting long-term treatment with low-sodium oxybate in adults with idiopathic hypersomnia. Registry: ClinicalTrials.gov; Name: A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension; URL: https://clinicaltrials.gov/study/NCT03533114; Identifier: NCT03533114 and Registry: EU Clinical Trials; Name: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension; URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001311-79/results; Identifier: 2018-001311-79. Morse AM, Dauvilliers Y, Arnulf I, et al. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia.

Identifiants

pubmed: 37409509
pii: jcsm.10698
doi: 10.5664/jcsm.10698
pmc: PMC10545992
doi:

Substances chimiques

Sodium Oxybate 7G33012534

Banques de données

ClinicalTrials.gov
['NCT03533114']

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1811-1822

Informations de copyright

© 2023 American Academy of Sleep Medicine.

Références

Neurology. 2019 Apr 9;92(15):e1754-e1762
pubmed: 30867266
Brain. 1997 Aug;120 ( Pt 8):1423-35
pubmed: 9278632
Sleep Med Clin. 2017 Sep;12(3):331-344
pubmed: 28778232
Sleep. 2003 Feb 1;26(1):31-5
pubmed: 12627729
Sleep Med. 2020 Dec;76:104-112
pubmed: 33152582
Sleep. 2007 Oct;30(10):1274-81
pubmed: 17969461
CNS Drugs. 2023 Apr;37(4):323-335
pubmed: 36947322
Sleep Med. 2013 Jan;14(1):30-6
pubmed: 23036267
J Sleep Res. 2015 Feb;24(1):74-81
pubmed: 25196321
Sleep Med Rev. 2023 Jun;69:101766
pubmed: 36921459
Sleep Med. 2019 Mar;55:1-5
pubmed: 30735912
Lancet Neurol. 2022 Jan;21(1):53-65
pubmed: 34942138
Sleep Med. 2020 Nov;75:343-349
pubmed: 32950878
Lancet Child Adolesc Health. 2018 Jul;2(7):483-494
pubmed: 30169321
Sleep. 2018 Sep 1;41(9):
pubmed: 29986085
J Clin Sleep Med. 2022 Feb 01;18(2):617-629
pubmed: 34596041
Drugs Real World Outcomes. 2021 Mar;8(1):15-28
pubmed: 33439474
Sleep Med. 2021 Apr;80:315-321
pubmed: 33631500
Sleep. 2009 Jul;32(7):915-9
pubmed: 19639754
Nat Sci Sleep. 2022 Oct 26;14:1901-1917
pubmed: 36320423
N Engl J Med. 1995 Nov 9;333(19):1291
pubmed: 7566018
Sleep Med. 2014 Jun;15(6):681-7
pubmed: 24854887
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Sleep Med Rev. 2022 Dec;66:101709
pubmed: 36401976
Sleep. 2021 Mar 12;44(3):
pubmed: 33184650
Sleep. 2014 Mar 01;37(3):483-7
pubmed: 24587570
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Sleep Med. 2016 Jan;17:38-44
pubmed: 26847972

Auteurs

Anne Marie Morse (AM)

Janet Weis Children's Hospital, Geisinger, Danville, Pennsylvania.

Yves Dauvilliers (Y)

Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.
University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France.

Isabelle Arnulf (I)

Sleep Disorder Unit, Pitié-Salpêtrière Hospital and Sorbonne University, Paris, France.

Michael J Thorpy (MJ)

Albert Einstein College of Medicine, Bronx, New York.

Nancy Foldvary-Schaefer (N)

Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.

Patricia Chandler (P)

Jazz Pharmaceuticals, Palo Alto, California.

Abby Chen (A)

Jazz Pharmaceuticals, Palo Alto, California.

Luke Hickey (L)

Jazz Pharmaceuticals, Philadelphia, Pennsylvania.

Jed Black (J)

Jazz Pharmaceuticals, Palo Alto, California.
Stanford Center for Sleep Sciences and Medicine, Palo Alto, California.

Richard K Bogan (RK)

University of South Carolina School of Medicine, Columbia, South Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH